Last week, the company updated its revenue guidance to $72 million to $74 million for FY 2015.
EndoChoice stock has a 52-week high of $19.69 and a 52-week low of $7.37, according to the report.
More articles on gastroenterology:
Exact Sciences to open biotech campus & more – 3 GI company key notes
CMS cuts to colonoscopy reimbursement finalized: 3 things to know
6 recent must-reads on CRC screening & treatments
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
